Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited (ASX:IMU) for $6 million on April 16, 2024. Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.071 AUD | +1.43% | -5.33% | -35.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.45% | 342M | |
+33.52% | 49.46B | |
+1.70% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.16% | 18.64B | |
+7.83% | 13.16B | |
+29.52% | 12.55B | |
+24.11% | 12.1B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.